Noray Biosciences Group, founded in December 2006, is an entrepreneurial group focussed on Biosciences, situated among the ten first companies of the Spanish Biotechnology sector.

The Group is made up of two companies to the moment, Histocell and Noray Bioinformatics S.L.U. (NorayBio).

Noray BG’s objective is to manage and integrate the companies, looking for synergies in processes and markets, for its growth and internationalization, which allow them to compete in the global market of Biotechnology.

Group founding members and directors of the group and the two companies are Julio Font, president, and Marta Acilu, vice-president.

Noray BG stands out for its innovation management model, based on efficiency and search of solutions for the real needs of the Biotechnology sector.

The Group was created by NorayBio founders after the acquisition of the majority of Histocell in December 2006. In that moment, joined ORZA A.I.E., made up of pension fund entities GEROA and ELKARKIDETZA, to reinforce company’s capital and strength.

Noray BG stands out for its innovation management model, based on efficiency and search of solutions for the real needs of the Biotechnology sector. Through the income generated from the sale of these products and services in the short term, Noray BG’s growth is defrayed with own resources that allow the company to cover the R&D necessary for innovation. Noray BG assigns 60% of its expenses to R&D.

Noray BG’s strategy for the near future is based on the continuous growth by means of collaboration agreements with other companies and institutions, development of new innovative products and acquisition or merger with new firms.
Everything done with the firm idea of motivating the expansion throughout the European and international market, making the most out of the synergies among the Group companies.